FDA review
![bimekizumab fda approval, ucb plaque psoriasis drug, bimekizumab review extension, ucb bimekizumab manufacturing, bimekizumab efficacy and safety, bimekizumab european commission approval, bimekizumab il-17 inhibitor](https://pharmtales.com/wp-content/uploads/2023/09/UCBs-psoriasis-drug-application-overcomes-manufacturing-hurdle-but-hits-another-FDA-delay.jpg)
UCB’s psoriasis drug application overcomes manufacturing hurdle but hits another FDA delay
Anika Sharma
After facing delays related to manufacturing issues, UCB’s psoriasis medication, bimekizumab, is awaiting the next steps in its FDA review ...